桐城哪里算卦比较准(广饶算命需要多少钱) (今日更新中)

NEW YORK — An influential scientific panel on Tuesday voted to recommend to the CDC that when a COVID-19 vaccine becomes available, both front line health care workers and residents in long-term care facilities should be prioritized first. The Advisory Committee on Immunization Practices voted 14-1 in favor of adopting the following recommendation: When a COVID-19 vaccine is authorized by FDA and recommended by ACIP, vaccination in the initial phase of the COVID-19 vaccination program (Phase 1a) should be offered to both 1) health care personnel and 2) residents of long-term care facilities.Watch the meeting live here."About one (American) dies every minute from COVID-19. During this ACIP meeting, about 120 people will die," Dr. Beth Bell said during initial remarks at the beginning of the virtual meeting Tuesday.The ACIP met Tuesday afternoon in an open-to-the-public, virtual meeting to vote on the proposal that gives priority to health care workers and patients in nursing homes and other long-term care facilities. The two groups together represent around 23 million Americans out of a population of about 330 million; about 21 million in health care professions and less than 3 million adults living in long-term care facilities.Current estimates project around 40 million doses combined available by the end of 2020. And each vaccine product requires two doses.The CDC said Tuesday they expect 5-to-10 million doses available each week after a vaccine is authorized by the FDA. They say these numbers necessitate the need for sub-group prioritizing, since not all health care workers or long-term care facilities can be vaccinated at once. Another consideration the panel discussed is not having an entire unit or group get vaccinated at once; if there are side effects like fatigue or other symptoms that necessitates taking a day or two off, this could leave a unit critically short-staffed. During Tuesday's presentation, Dr. Kathleen Dooling talked about statistics from COVID-19 patients in the US and how it lead to health care workers and long-term facility staff and patients to be at the top of the vaccine list. Long-term care facilities are responsible for six percent of COVID-19 cases and 40 percent of COVID-19 deaths in this country, she said. Later this month, the Food and Drug Administration will consider approval of two vaccines made by Pfizer and Moderna. The panel meeting Tuesday said they hope to learn more about the safety and effectiveness of the vaccines as more information is released by the FDA.Dr. Dooling said one of the questions they hope to ask about the Phase 3 trial data of both Pfizer and Moderna is how effective one dose of the vaccine has shown to be. They will also be taking a deeper look at the age groups of those included in the trial, and the efficacy of the vaccines on older people. Some of the comments during the public comment section referenced the lack of transparency released at this time about the vaccines and the panel trying to make vaccination decisions without it. However, the panel, while voting, expressed faith in the FDA's process of approving the vaccine as safe for all Americans. Once vaccines are given, the CDC and FDA will be asking all health care providers and facilities to use the existing Vaccine Adverse Event Reporting System, VAERS, to monitor any side effects and adverse reactions to the COVID-19 vaccines. The advisory panel will meet again at some point to decide who should be next in line. Among the possibilities: teachers, police, firefighters and workers in other essential fields such as food production and transportation; the elderly; and people with underlying medical conditions.Experts say the vaccine will probably not become widely available in the U.S. until the spring.ACIP is a 15-member panel of outside scientific experts, created in 1964, that makes recommendations to the director of the Centers for Disease Control and Prevention, who almost always approves them. Childhood vaccine schedules are one example of the work of this group. The recommendations are not binding, but for decades they have been widely heeded by doctors, and they have determined the scope and funding of U.S. vaccination programs.It will be up to state authorities whether to follow the guidance. It will also be left to them to make further, more detailed decisions if necessary — for example, whether to put emergency room doctors and nurses ahead of other health care workers if vaccine supplies are low. 4517

NEW YORK (AP) — A judge has denied President Donald Trump's request that the United States replace him as the defendant in a defamation lawsuit that alleges that he raped a woman in a Manhattan luxury department store in the 1990s.The decision Tuesday by U.S. District Judge Lewis A. Kaplan came after the Justice Department argued that the U.S. and by extension American taxpayers should replace Trump as the defendant in the lawsuit filed by E. Jean Carroll.The judge ruled that Trump's public denials of the rape allegation came outside the scope of his employment as president.The Washington Post obtained Kaplan’s 59-page ruling, which said Trump didn’t qualify as a federal “employee” and that he wasn’t acting “within the scope of his employment” when he denied Carroll’s rape allegation during 2019 interviews.During those interviews, Trump claimed Carroll was “totally lying” to sell a book and denied ever meeting her, though they were photographed together in the late 1980s.Carroll’s lawsuit claims the president harmed her reputation when he denied the allegation and branded her a liar, The New York Times reports. 1136

New results on a possible COVID-19 vaccine from Oxford University and drugmaker AstraZeneca suggest it is safe and about 70% effective.Some experts say that shows it is likely to win approval, but questions remain about how well it may help protect those over 55. That's a key concern for a vaccine that health officials hope to rely on around the world because of its low cost, availability and ease of use.Partial results from tests of the vaccine in the United Kingdom, Brazil and South Africa were published Tuesday by the medical journal Lancet.“Today, we have published the interim analysis of the Phase III trial and show that this new vaccine has a good safety record and efficacy against the coronavirus,” said Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial. “We are hugely grateful to our trial volunteers for working with us over the past eight months to bring us to this milestone.”Researchers claim the vaccine protected against disease in 62% of those given two full doses and in 90% of those initially given the half dose. However, independent experts have said the second group was too small — 2,741 people — to judge the possible value of that approach and more testing is needed.The interim analysis for efficacy was based on 11,636 participants accruing 131 symptomatic infections from the Phase III trials.In addition to the Oxford led program, AstraZeneca is conducting a large study in the US and globally. In total, Oxford University and AstraZeneca expect to enroll more than 60,000 participants globally.The company says it’s also making progress in manufacturing with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval. The vaccine can be stored, transported and handled at normal refrigerated conditions for at least six months and administered within existing health care settings. 1940

NEW YORK (AP) — Macy’s said Thursday that it’s laying off 3,900 corporate staffers, roughly 3% of its overall workforce, as the pandemic takes a financial toll on the retailer's sales and profits.The headcount reduction will save the department store chain 0 million per year.Like many of its non-essential peers, Macy’s was forced to close its physical stores to curb the spread of the coronavirus, evaporating sales.Since early May, Macy’s has been gradually reopening its stores, which had been closed since March 18.The New York-based company furloughed a majority of its workers as the pandemic took hold in the U.S. However, it was announced Thursday that most remaining furloughed employees would be returning to work starting July 5.Macy’s CEO Jeff Gennette has said that customers are coming back, but it needs to cut costs to readjust its business to a new climate.“COVID-19 has significantly impacted our business. While the re-opening of our stores is going well, we do anticipate a gradual recovery of business, and we are taking action to align our cost base with our anticipated lower sales,” said Gennette. “These were hard decisions as they impact many of our colleagues. I want to thank all of our colleagues – those who have been active and those on furlough – for helping us get through this difficult time, and I want to express my deep gratitude to the colleagues who are departing for their service and contributions. We look forward to welcoming back many of our furloughed colleagues the first week of July.” 1544

Nestle and Starbucks are teaming up to create a "global coffee alliance."Under the deal, Nestle will pay .2 billion to market, sell and distribute Starbucks' packaged products around the world, the companies said Monday.Nestle already has a significant presence in the coffee business with well-known brands like Nescafe and Nespresso. It's now adding Starbucks coffee and tea products to the list.The agreement only covers Starbucks' packaged goods sold outside the US company's stores. It doesn't include Starbucks' ready-to-drink coffee, tea or juices.Starbucks CEO Kevin Johnson said the deal "will bring the Starbucks experience to the homes of millions more around the world."The deal still needs approval from regulators and is expected to be finalized in summer or early fall this year, the companies said.About 500 Starbucks employees will join Nestle under the agreement, the Switzerland-based company said.It said the Starbucks packaged goods business generates annual revenue of about billion a year.  1031

来源：资阳报